| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 05/08/2001 | US6228359 Treatment of autoimmune diseases by removal of cells and inhibitors |
| 05/08/2001 | CA2324484A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323464A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323191A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2323183A1 Compounds for the treatment of female sexual dysfunction |
| 05/08/2001 | CA2167040C New alkylated (hetero)cyclic compounds; process for preparing the same and pharmaceutical compositions containing them |
| 05/08/2001 | CA2141961C Antioxidant |
| 05/08/2001 | CA2032141C Pharmaceutically active agents that impede amyloid formation in vivo |
| 05/03/2001 | WO2001031045A1 Mammalian-type glycosylation in plants |
| 05/03/2001 | WO2001031029A2 Human sphingosine kinase gene |
| 05/03/2001 | WO2001031007A2 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | WO2001030987A2 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 05/03/2001 | WO2001030969A2 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | WO2001030845A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 05/03/2001 | WO2001030843A1 Ligand activated transcriptional regulator proteins |
| 05/03/2001 | WO2001030828A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | WO2001030812A2 Activation of hcv-specific t cells |
| 05/03/2001 | WO2001030793A1 Hygromycin a prodrugs |
| 05/03/2001 | WO2001030789A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | WO2001030781A2 INHIBITORS OF αLβ2 MEDIATED CELL ADHESION |
| 05/03/2001 | WO2001030779A1 Naphthyridine derivatives |
| 05/03/2001 | WO2001030777A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | WO2001030774A1 Substituted indoles for modulating nfkb activity |
| 05/03/2001 | WO2001030772A1 Compounds and their use as cysteine protease inhibitors |
| 05/03/2001 | WO2001030771A1 Thiazolidinedione derivatives |
| 05/03/2001 | WO2001030766A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | WO2001030763A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | WO2001030759A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | WO2001030752A2 Indole compounds for treating bacterial infections |
| 05/03/2001 | WO2001030750A1 Method of producing n-(4,5-bis-methanesulfonyl-2-methyl-benzoyl)-guanidine, the hydrochloride thereof |
| 05/03/2001 | WO2001030736A2 Aromatic di-keto derivatives as glucose-6-phosphate translocase inhibitors |
| 05/03/2001 | WO2001030734A1 Novel hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand |
| 05/03/2001 | WO2001030448A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | WO2001030395A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 05/03/2001 | WO2001030394A1 Treatment of cancer |
| 05/03/2001 | WO2001030388A1 Tension-relieving agents for ciliary muscle |
| 05/03/2001 | WO2001030387A1 Preventives or remedies for arrhythmia |
| 05/03/2001 | WO2001030383A2 Medicament in order to induce tolerance |
| 05/03/2001 | WO2001030375A2 Use of gdnf for treating corneal defects |
| 05/03/2001 | WO2001030353A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 05/03/2001 | WO2001030351A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | WO2001030350A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | WO2001030349A1 Amorphous paroxetine compositon |
| 05/03/2001 | WO2001030346A1 Treatment of dyskinesia |
| 05/03/2001 | WO2001030345A1 Clonidine preparations |
| 05/03/2001 | WO2001030341A1 Cyclooxygenase-2 expression inhibitors |
| 05/03/2001 | WO2001030326A1 Treatment of emphysema using rar selective retinoid agonists |
| 05/03/2001 | WO2001030313A1 Cosmetic compositions containing mulberry extract and retinoids |
| 05/03/2001 | WO2001030149A1 Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | WO2001030148A1 Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | WO2001005968A9 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 05/03/2001 | WO2001000221A3 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
| 05/03/2001 | WO2000077168A3 ANTAGONISTS OF BMP AND TGFβ SIGNALLING PATHWAYS |
| 05/03/2001 | WO2000074695A3 Tanacetum parthenium extract |
| 05/03/2001 | WO2000072876A3 Prevention and treatment of amyloidogenic disease |
| 05/03/2001 | WO2000065028A3 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 05/03/2001 | US20010000786 Administering to an obese canine a low supplemental amount of L-carnitine to promote weight loss, increase the lean body mass, enhance satiety and reduce voluntary food intake |
| 05/03/2001 | US20010000783 Associated with inhibited epithelial cell proliferation comprising administering a heparin-binding epidermal growth factor-like growth factor (HB-EGF) or derivative, e,g. anantiidiotypic antibody to HB-EGF, gene therapy; angonists |
| 05/03/2001 | US20010000730 Method of enhancing the efficacy of anti-tumor agents |
| 05/03/2001 | DE19952147A1 Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung New cyclopropanes, pharmaceutical compositions containing them and methods for their preparation |
| 05/03/2001 | DE19951970A1 Arzneimittel für die Toleranzinduktion Medicines for tolerance induction |
| 05/03/2001 | DE19951418A1 Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid Process for the preparation of N- (4,5-Bismethansulfonyl-2-methyl-benzoyl) guanidine, hydrochloride |
| 05/03/2001 | DE19951360A1 Substituierte Indole Substituted indoles |
| 05/03/2001 | DE19949595A1 CTAGE-Genfamilie CTAGE gene family |
| 05/03/2001 | DE19949202A1 Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure Transdermal therapeutic system for the delivery of acetylsalicylic acid and / or salicylic acid |
| 05/03/2001 | DE19949179A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid |
| 05/03/2001 | CA2389583A1 Method and compositions for administering taxanes orally to human patients |
| 05/03/2001 | CA2389217A1 Mammalian-type glycosylation in plants |
| 05/03/2001 | CA2389171A1 Ruthenium (ii) complexes with high antitumoral and antimetastatic activities |
| 05/03/2001 | CA2389127A1 Human sphingosine kinase gene |
| 05/03/2001 | CA2389020A1 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 05/03/2001 | CA2389019A1 Hygromycin a prodrugs |
| 05/03/2001 | CA2388998A1 Treatment of cancer |
| 05/03/2001 | CA2388974A1 Medicament in order to induce tolerance |
| 05/03/2001 | CA2388942A1 Therapeutic compositions and methods for treating disease states with mutant forms of myeloid progenitor inhibitory factor-2 (mpif-2) |
| 05/03/2001 | CA2388617A1 Nucleic acid molecules derived from rat brain and programmed cell death models |
| 05/03/2001 | CA2388611A1 Transdermal drug delivery devices |
| 05/03/2001 | CA2388535A1 Ligand activated transcriptional regulator proteins |
| 05/03/2001 | CA2388483A1 Process for producing optically active naphthalene derivative and optical resolver therefor |
| 05/03/2001 | CA2388479A1 Preventives or remedies for arrhythmia |
| 05/03/2001 | CA2388332A1 Tankyrase h, compositions involved in the cell cycle and methods of use |
| 05/03/2001 | CA2388121A1 Phthalazinone derivatives as pde 4 inhibitors |
| 05/03/2001 | CA2388119A1 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors |
| 05/03/2001 | CA2388077A1 Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections |
| 05/03/2001 | CA2387685A1 Stanniocalcin proteins and nucleic acids and methods based thereon |
| 05/03/2001 | CA2387680A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 05/03/2001 | CA2387648A1 Oral formulations for anti-tumor compounds |
| 05/03/2001 | CA2386908A1 Treating sleep disorders using desloratadine |
| 05/03/2001 | CA2385929A1 Use of gdnf for treating corneal defects |
| 05/03/2001 | CA2385178A1 Naphthyridine derivative |
| 05/02/2001 | EP1096016A1 Platelet-activating factor acetylhydrolase |
| 05/02/2001 | EP1096008A2 Human G protein-coupled receptor, PFI-014 |
| 05/02/2001 | EP1095936A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
| 05/02/2001 | EP1095933A1 Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them |
| 05/02/2001 | EP1095658A2 Use of ribose to treat fibromyalgia |
| 05/02/2001 | EP1095657A2 Compositions for the regulation of cytokine activity |
| 05/02/2001 | EP1095654A2 Use of raloxifene and its analogs for the manufacture of a medicament for the Inhibition of LDL oxidation and atherosclerosis |
| 05/02/2001 | EP1095279A1 Method for identifying a presenilinase inhibitor |
| 05/02/2001 | EP1095275A2 Endogenous constitutively activated g protein-coupled orphan receptors |
| 05/02/2001 | EP1095274A1 Trifunctional reagent for conjugation to a biomolecule |